OUYE SubQ plus
€28.43
OUYE Sub-Q Plus offers high viscosity and elasticity for effective volumising and contouring. Ideal for correcting nasolabial folds and enhancing the chin, this hypoallergenic filler includes lidocaine for a comfortable, painless procedure. Designed for deep skin layers, it provides quick, natural-looking results lasting over 12 months.
1 Syringe × 1.0 ml
For professional use only.
Description
OUYE Sub-Q Plus – Advanced Hyaluronic Acid Dermal Fillers
OUYE Sub-Q Plus is a premium hyaluronic acid dermal filler designed for deep volumizing and contouring. With its advanced formulation, OUYE Sub-Q Plus is ideal for addressing nasolabial folds, chin augmentation, and precise body contouring.
Key Features:
- Advanced Formulation: The product’s high viscosity and elasticity provide effective volumizing and contouring with natural-looking results.
- Long-Lasting Effects: The benefits of this filler extend for over 12 months.
- Safe and Comfortable: The hypoallergenic composition includes lidocaine, ensuring a pain-free procedure.
- High Biocompatibility: This filler offers quick and lasting results with minimal risk of side effects.
Treatment Areas:
- Nasolabial folds
- Chin augmentation
- Body contouring
Composition:
- Hyaluronic Acid concentration: 24mg/ml
- Lidocaine HCl: 0.3%
- Volume: 1.0ml per syringe
- Needle Size: 27G
Box Contents:
- 1x syringe for precision application
- 1x sterile needle to ensure safety
Quality Assurance:
OUYE Sub-Q Plus products undergo rigorous safety tests, ensuring you receive only the highest quality.
Note on Usage:
For the best results, avoid using OUYE Sub-Q Plus in pregnant or breastfeeding women, individuals under the age of 18, patients with hypersensitivity to hyaluronic acid or lidocaine, those prone to hypertrophic scarring, and areas with inflammation or infection. It is also advisable to avoid immediate use before or after treatments such as laser therapy, chemical peels, or dermabrasion.
You must be logged in to post a review.
Reviews
There are no reviews yet.